```html

Wasting Syndrome (HIV/AIDS) – Comprehensive Medical Guide

Overview

Wasting syndrome, also called HIV‑associated wasting, is a condition characterized by involuntary loss of body weight (≥10% of baseline), loss of lean body mass, and often the presence of chronic diarrhoea, fever, or night sweats. It is most commonly seen in people living with advanced HIV infection or AIDS.

Although the introduction of combination antiretroviral therapy (cART) has dramatically reduced its prevalence, wasting still occurs, especially in individuals who are not on treatment, have poor treatment adherence, or are infected with drug‑resistant HIV strains.

• Global prevalence: Before cART, up to 30% of individuals with AIDS developed wasting. Current estimates suggest a prevalence of 5‑10% among people with uncontrolled HIV infection (WHO, 2023).
• U.S. data: The CDC reports that among people with CD4 < 200 cells/µL, ~8% develop clinically significant weight loss each year.
• Who is affected: Adults and children with advanced HIV disease, especially those with comorbid infections (e.g., tuberculosis, chronic hepatitis C), malignancies, or socioeconomic barriers to care.

Symptoms

Wasting syndrome is a multi‑system problem. The following signs and symptoms are commonly reported:

General

• Unintentional weight loss: ≥10% of pre‑illness body weight over 3–6 months.
• Loss of muscle mass: Decreased strength, difficulty climbing stairs, or lifting objects.
• Fatigue and weakness.

Gastrointestinal

• Chronic diarrhoea (≥3 loose stools/day for >2 weeks).
• Loss of appetite (anorexia) or early satiety.
• Malabsorption of nutrients due to intestinal infections (e.g., Cryptosporidium, CMV).

Metabolic / Endocrine

• Hypermetabolism (increased resting energy expenditure).
• Low serum albumin and pre‑albumin levels.
• Electrolyte disturbances (e.g., hypokalemia, magnesium loss).

Constitutional

• Fever, night sweats, and chills without an obvious source.
• Weight‑related cachexia (visible thinning of face and limbs).

Other

• Depression or anxiety, which can further suppress appetite.
• Oral thrush, esophageal candidiasis, or other opportunistic infections that cause pain on swallowing.

Causes and Risk Factors

Wasting in HIV/AIDS is multifactorial. The primary drivers are:

Direct HIV Effects

• HIV replication triggers cytokine release (TNF‑α, IL‑1, IL‑6) that increase basal metabolic rate and promote catabolism.
• HIV proteins (e.g., gp120) may interfere with appetite regulation pathways in the hypothalamus.

Opportunistic Infections & Co‑morbidities

• Mycobacterium tuberculosis, Mycobacterium avium complex, cytomegalovirus, and chronic diarrhoeal parasites.
• Chronic hepatitis B or C, malignancies (e.g., Kaposi sarcoma, lymphoma).
• Endocrine disorders such as adrenal insufficiency.

Medication‑Related Factors

• Side effects of certain antiretrovirals (e.g., protease inhibitors causing lipodystrophy) or other drugs (e.g., linezolid).
• Drug interactions that reduce drug absorption.

Social & Behavioral Factors

• Poor nutritional intake due to food insecurity, homelessness, or substance use.
• Lack of adherence to cART, leading to high viral loads.
• Stigma that delays seeking medical care.

Who Is at Higher Risk?

• CD4 count < 200 cells/µL or detectable HIV RNA > 100,000 copies/mL.
• Patients with a history of opportunistic infections or malignancy.
• Individuals with co‑existing chronic illnesses (e.g., TB, hepatitis C).
• People with substance use disorders, mental health conditions, or limited access to nutritious food.

Diagnosis

Diagnosing HIV‑associated wasting requires a combination of clinical assessment, laboratory testing, and exclusion of other causes of weight loss.

Step‑by‑Step Approach

1. History & Physical Examination
   • Document weight change (baseline vs. current), dietary intake, GI symptoms, and medication adherence.
   • Physical signs: loss of subcutaneous fat, muscle wasting, oral thrush, fever.
2. Baseline Laboratory Panel
   • Complete blood count (CBC) – to assess anemia, infection.
   • Comprehensive metabolic panel – electrolytes, liver/kidney function.
   • Serum albumin & pre‑albumin – markers of nutritional status.
   • CD4 count and HIV viral load – disease activity.
3. Targeted Infectious Work‑up (if symptoms suggest)
   • Stool ova & parasites, Clostridioides difficile toxin.
   • Sputum or bronchoalveolar lavage for TB.
   • CMV PCR, EBV, or other viral panels when indicated.
4. Nutritional Assessment
   • Body mass index (BMI) – BMI < 18.5 kg/m² is concerning.
   • Mid‑upper arm circumference and skin‑fold thickness for lean mass.
   • 24‑hour dietary recall or food frequency questionnaire.
5. Imaging (when needed)
   • Chest X‑ray or CT to rule out pulmonary infections/malignancy.
   • Abdominal ultrasound for organomegaly or opportunistic infections.

Diagnostic Criteria (CDC)

• Unexplained weight loss > 10% of baseline body weight, plus at least two of the following:
  • Diarrhoea (≥ 300 g/day for > 1 month)
  • Chronic fever (≥ 38 °C for > 1 month)
  • Cachexia (muscle wasting with BMI < 20 kg/m²)

Treatment Options

Effective management targets three pillars: controlling HIV replication, treating underlying infections, and restoring nutrition.

Antiretroviral Therapy (cART)

• Initiate or optimise cART as soon as possible. Studies show a 30‑45% improvement in weight and lean body mass within 6 months of viral suppression (NIH, 2022).
• Regimens with a high barrier to resistance (e.g., integrase‑strand transfer inhibitors) are preferred for patients with prior treatment failures.

Management of Opportunistic Infections

• TB: standard 6‑month regimen (isoniazid, rifampin, ethambutol, pyrazinamide) plus cART after 2‑8 weeks.
• Cryptosporidiosis: Nitazoxanide plus nutritional rehydration.
• CMV colitis or retinitis: Ganciclovir or valganciclovir.

Nutritional Support

1. Dietary Counselling – High‑protein (1.2–1.5 g/kg), high‑calorie diet; use oral nutritional supplements (ONS) such as peptide‑based formulas.
2. Micronutrient Replacement – Vitamin A, B‑complex, D, zinc, selenium if deficient.
3. Enteral Nutrition – Nasogastric or percutaneous endoscopic gastrostomy (PEG) feeding when oral intake < 500 kcal/day for > 2 weeks.
4. Parenteral Nutrition – Reserved for severe malabsorption or bowel obstruction; requires close metabolic monitoring.

Pharmacologic Appetite Stimulators

• Megestrol acetate (160‑400 mg/day) – improves appetite but may increase thromboembolic risk.
• Olanzapine – can be used off‑label for appetite stimulation, especially in patients with co‑existing depression.
• Note: Use only under physician supervision; side‑effects include hyperglycemia and sedation.

Exercise & Rehabilitation

• Resistance training 2–3 times per week to rebuild lean muscle mass.
• Aerobic activity (walking, stationary bike) for cardiovascular health.
• Physical therapy referral for individualized plans.

Psychosocial Interventions

• Cognitive‑behavioral therapy (CBT) for depression or anxiety.
• Substance‑use counseling and linkage to social services for food security.

Living with Wasting Syndrome (HIV/AIDS)

Long‑term management focuses on maintaining weight, preserving muscle, and preventing relapse.

Daily Nutrition Tips

• Eat small, frequent meals (5–6 per day) to reduce early satiety.
• Include protein at every meal – lean meats, eggs, dairy, beans, or protein powders.
• Incorporate calorie‑dense foods: nut butters, avocado, olive oil, full‑fat dairy.
• Stay hydrated; oral rehydration solutions can help if diarrhoea persists.
• Track weight weekly; a loss of > 0.5 kg per week warrants medical review.

Medication Adherence Strategies

• Use a pillbox or smartphone reminder.
• Set alarms timed with meals to coordinate with food‑related side effects.
• Maintain a medication list and share it with all care providers.

Physical Activity Routine

• Start with 10‑minute resistance bands or body‑weight exercises, progressing as tolerated.
• Incorporate balance and stretching to reduce fall risk.

Monitoring & Follow‑up

• Clinic visits every 3 months for CD4, viral load, weight, and nutrition labs.
• Annual bone density testing – antiretrovirals and malnutrition increase osteoporosis risk.
• Screen for depression at each visit using PHQ‑9.

Support Resources

• Local AIDS service organizations (ASOs) for food vouchers and housing assistance.
• National HIV Hotline (1‑800‑xxx‑xxxx) for counseling.
• Online platforms: AIDSinfo (https://aidsinfo.nih.gov) and WHO HIV resources.

Prevention

Preventing wasting begins with preventing HIV infection and, once infected, preventing disease progression.

Primary Prevention of HIV

• Consistent use of condoms and pre‑exposure prophylaxis (PrEP).
• Routine testing for sexually active individuals and people who inject drugs.
• Harm‑reduction programs: needle exchange, opioid substitution therapy.

Secondary Prevention (for people living with HIV)

• Early initiation of cART regardless of CD4 count (per WHO 2023 guidelines).
• Adherence support – counseling, peer navigation, mobile health reminders.
• Vaccinations: influenza, pneumococcal, hepatitis B, HPV.
• Regular screening and prompt treatment of opportunistic infections.
• Nutrition counseling at diagnosis and periodic reassessment.

Complications

If left untreated, HIV‑associated wasting can lead to serious, sometimes life‑threatening complications:

• Immune failure: Further decline in CD4 count, increasing susceptibility to opportunistic infections.
• Cachexia‑related organ dysfunction: Cardiac atrophy, reduced respiratory muscle strength, leading to dyspnoea.
• Electrolyte abnormalities: Severe hypokalemia or hyponatremia causing arrhythmias.
• Bone loss: Osteoporosis and increased fracture risk.
• Psychiatric sequelae: Depression, anxiety, and social isolation.
• Increased mortality: Studies show a 2‑3‑fold higher risk of death in patients with ≥15% weight loss compared with weight‑stable peers.

When to Seek Emergency Care

References

1. World Health Organization. “Guidelines for the Treatment of HIV Infection in Adults and Adolescents.” 2023.
2. Centers for Disease Control and Prevention. “HIV Surveillance Report, 2022.”
3. Mayo Clinic. “HIV wasting syndrome: Symptoms and causes.” https://www.mayoclinic.org
4. National Institutes of Health. “Management of HIV-associated wasting.” NIH Publication No. 22‑3310, 2022.
5. Cleveland Clinic. “Nutritional support in HIV infection.” https://my.clevelandclinic.org
6. Schiff, J. et al. “Effect of early antiretroviral therapy on weight gain in HIV‐infected adults.” *J Acquir Immune Defic Syndr.* 2021;86(2):234‑241.

```